Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.60 |
| ▸ | HTR2A | P28223 | 12/20 | 0.60 |
| ▸ | DRD2 | P14416 | 7/20 | 0.55 |
| ▸ | DRD1 | P21728 | 7/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30579711 | 1.00 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL22023339 | 1.00 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL5515239 | 0.90 | OPRM1 (0.49) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL25342053 | 0.87 | OPRM1 (0.55) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL31659338 | 0.86 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL22118530 | 0.86 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL22118531 | 0.86 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL21699949 | 0.86 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL3304883 | 0.86 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL30641165 | 0.86 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145659-A1 | HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3897621-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132605-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| CN-110831941-A | Synthesis of substituted heterocycle fused gamma-carboline compound | 细胞内治疗公司 | 2020-02-21 | — | — | CN | disclosed |
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7183282-B2 | Substituted heterocycle fused γ-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2006-07-06 | — | — | US | disclosed |
| US-7071186-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1189904-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | ROBICHAUD ALBERT J (US) | 2004-02-19 | — | — | US | disclosed |
| US-6552017-B1 | As serotonin agonists and antagonists and are useful in the control or prophylaxis of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | OPRM1 19/4885HTR2A 30/4885DRD2 16/4885 |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | HTR2B, HTR1B, HTR3B | OPRM1 39/4885HTR2A 17/4885DRD2 11/4885 |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | OPRM1 19/4885HTR2A 30/4885DRD2 16/4885 |
| US-20220048910-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | OPRM1 2/4885HTR2A 6/4885DRD2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.